Leflunomide
- TRADE NAME: Arava (Sanofi-Aventis)
- INDICATIONS: Rheumatoid arthritis
- CLASS: Disease-modifying antirheumatic drug (DMARD), Tyrosine kinase inhibitor
- HALF-LIFE: 14–15 days
Alefacept, Azacitidine, BCG Vaccine, Betamethasone, Cabazitaxel, Carvedilol, Cholestyramine, CYP2C9 substrates, Denileukin, Denosumab, Docetaxel, Echinacea, Fingolimod, Gefitinib, Immunosuppressants, Lenalidomide, Live vaccines, Methotrexate, Natalizumab, Oxaliplatin, Pazopanib, Pemetrexed, Phenytoin, Pimecrolimus, Pralatrexate, Pralatrexate, Rifampin, Tacrolimus, Temsirolimus, Teriflunomide, Tolbutamide, Trastuzumab, Triamcinolone, Typhoid Vaccine, Vitamin K antagonists, Warfarin, Yellow Fever Vaccine
PREGNANCY CATEGORY: X
Investigated for treating COVID-19.
Please login to see the rest of this drug profile
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of leflunomide in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 01/22/2023
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
